retatrutide safety trial Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Triple hormone receptor agonist retatrutide

Gokdemir MT, Gokdemir GS, Tas M

Qsymia fits patients who prefer oral dosing, have moderate weight to lose (20 to 40 pounds), can tolerate the topiramate side effect profile, and have a budget constraint or insurance that doesnt cover GLP-1s for obesity

If you're taking insulin or sulfonylureas alongside your GLP-1 medicine, your healthcare provider may need to adjust these doses to reduce the risk of hypoglycaemia, which can itself cause headaches

and foam cell formation and endothelial cell apoptosis, which reduces the atherosclerotic plaques necrotic core

Counterfeit Botox that sickened people across the country in April 2024 (FDA) An August 2025 expos in Elle about bad actors and loose regulation in the medical spa industry included the story of a Boston woman who falsely claimed to be a registered nurse and injected patients with counterfeit products from Brazil and China